CytomX Therapeutics, Inc., incorporated on September 16, 2010, is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, probody drug conjugates (PDCs), T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies to be delivered in an inactive state and then to be activated at the tumor site.
The Company's investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as Programmed death-ligand 1 (PD-L1), against which CX-072 is directed, as well as targets, such as cluster of differentiation 166 (CD-166), against, which CX-2009 is directed. CX-072 is a PD-L1 targeting Probody therapeutic for the treatment of cancer. CX-2009 is a PDC targeting CD166. Its CD71, also known as transferrin receptor 1 (TfR1), is a protein that is essential for iron uptake in dividing cells, is expressed in various solid and hematologic cancers and has molecular properties for delivery of cytotoxic payloads to tumor cells. CTLA-4 is an immune checkpoint involved in regulating T-cell activation. CTLA-4 antibodies lead to T-cell activation for a range of antigens, including tumor antigens, which is the basis for its anti-tumor effect, and self-antigens, which may be the basis for the autoimmune toxicities associated with CTLA-4 antibodies therapies. PD-1 is the receptor for the PD-L1 ligand responsible for inhibiting T-cell activation. It is the target for various immuno-oncology products, including nivolumab and pembrolizumab, which have been approved for melanoma.
The Company competes with AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer, Roche Holding Ltd, Sanofi SA, ImmunoGen, Inc. and Seattle Genetics, Inc.
151 Oyster Point Blvd Ste 400
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 2008.| Ticker | CTMX |
| Long Name | CytomX Therapeutics, Inc. |
| Short Name | CytomX Therapeutics |